Intelligence to accelerate human health

AI is one of the most transformational technologies in human history. It will have the impact of the industrial revolution, but it's moving much more rapidly. Making generally intelligent behavior abundantly accessible will reshape how we work, how we interact, how society operates, how we think.

Nowhere is the promise greater than in human health. Modern medicine is incredible. In life expectancy, in infant mortality, in treatments for diseases that were death sentences a generation ago, the progress is extraordinary. Future progress depends on discovering new therapies and getting them into the right patients' hands at the right time and the right way.

AI can dramatically accelerate progress, developing new treatments faster and helping every patient get better care. And unlike previous waves of technology, AI's capabilities are improving at an exponential pace. The gap between what AI can do for healthcare and what has been deployed is enormous, and growing. Every month that gap persists, we lose patients who could be helped. 

Closing the gap between AI capabilities and patient impact is the most important work in healthcare today.

Patients deserve the best that technology can offer. We hold, as a core founding belief, that bringing the best ways technology works to healthcare will improve patient outcomes. For over a decade, we have been working to do that, building consumer-grade experiences and bringing AI into the multiparty, regulated workflows that define how care and treatment reach patients. 

We've learned what it takes to make AI work in healthcare. Through many cycles of building, deploying, and iterating on AI in medical workflows, and from watching where others have succeeded and where they've failed, we've come to understand what closes the gap between what technology promises and what it delivers. As model capabilities have multiplied, so has the value of those lessons. You need to:

1. Build direct partnerships with patients. Patients are who healthcare is for. Working with them is both the most effective way to build and the right thing to do: earning trust, designing from their needs, and respecting that they own their data and choose how it's used.

2. Meet healthcare where it is. In the face of healthcare’s complexity, it’s tempting to go around the existing system, but that’s ultimately ineffective. Healthcare is complicated for a reason: bodies are complicated, treatments take deep specialization, and the state of the art keeps changing. The improvements that last integrate with the system, where care is actually delivered.

3. Overcome context fragmentation. AI works when it can access and navigate full context. Bringing context together in healthcare means unifying fragmented systems and organizing around the person at the center: the patient in care, the participant in research. The patient is the thread that connects every site, every system, every visit.

4. Rapidly establish clinical validity. When capabilities are moving so fast and the potential for impact is so high, shipping fast matters more than ever. But if you erode trust with patients, providers, scientists, or regulators, it’s counterproductive. You need quality controls that are robust and much faster than traditional mechanisms: continuously running evaluation, instant expert escalation, and validation across points of patient and scientific impact.

5. Integrate medical expertise into product build. To build effective AI systems in healthcare, the standard product development functions are necessary but not sufficient. You need clinical, scientific, operational, and regulatory expertise in the build process. The problems that most determine patient outcomes sit at the intersection of all of them, and solving them means assembling teams that have understanding across every domain.

We've seen that the biggest opportunities are the ones that are hardest to reach, where technology has historically struggled and where the potential for outsized impact has gone unrealized. So that’s where we focus.

Today, the most effective way to help patients at scale is developing new therapies. Better treatments for the chronic diseases that increasingly define how people die, cures for conditions we can only manage today, drugs that reach patients quickly enough to matter. The work happening in AI for drug discovery — identifying new targets, better screening, understanding pharmacokinetics — holds tremendous promise for finding more candidate treatments for more diseases than ever before. There are dozens of companies pushing this forward, and that is incredibly promising.

But, AI drug discovery won’t translate into more therapies reaching patients until the clinical trial bottleneck gets solved.

Clinical research is two-thirds of the cost and two-thirds of the time it takes to get a drug through development and to patients. It is the rate-limiting step between a promising asset and an actual treatment in a patient's hands. This is what needs to change to unlock the potential of any new asset uncovered by AI-powered drug discovery.

Think about what this means for the rare disease patient whose best hope was a promising treatment that got deprioritized because the investment couldn't be justified at today's cost of running a trial. Or the family watching the clock run out on a loved one while a program that might have helped slowly slogs through Phase III. Every drug that doesn't get developed, every trial that takes five years instead of two, every program cut because the math doesn't work, means real people losing their best hope for a cure.

If you change the economics of development by making trials faster, cheaper, and more reliable, it means more new therapies in patients’ hands. Faster trials mean more time under patent and more revenue, a stronger financial case for developing each drug. Cheaper, more reliable trials mean more assets clear the threshold for positive expected value, so more drugs get pushed through the pipeline. This means more safe and effective treatments reaching patients, faster. 

A far broader set of treatments becomes viable when research gets dramatically more efficient.

Much of the work that makes clinical research slow and expensive is exactly what AI is best at. Running trials is painstakingly detail-oriented, process-driven, and manual work: reconciling records across unconnected e-clinical systems, checking eligibility one chart at a time, keeping dozens of study documents consistent as protocols change. Much of it is overhead, not science. It’s hard to come up with a better-suited use case for AI. If fragmented context can be brought to one place, AI can make these processes faster, more efficient, and higher quality. 

Direct relationships with patients can restructure clinical development for dramatic acceleration. Traditional clinical research isn’t designed around patients as the primary stakeholder. Changing that can pull approval timelines forward: pre-engaged patient communities accelerate recruitment, seamless experiences improve retention, direct-to-patient biomarkers can speed time to readout with novel endpoints, long-term follow-up enrollment from the start can make Phase IVs redundant. The science works better when you work directly with the patients the science is for.

PicnicResearch is building this. We bring together scientific expertise, direct patient relationships, and AI-powered research infrastructure to make clinical research fundamentally better. We design patient-connected studies that generate stronger evidence, faster. These aren’t marginal improvements to how trials run today; they could cut the clinical development cycle in half. We are changing the ROI calculation on drug development itself, to unlock an abundance of new treatments for patients.